Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  González, Pablo A ^a   Carreño, Leandro J ^a   Céspedes, Pablo F ^a   Bueno, Susan M ^a,b   Riedel, Claudia A ^c   Kalergis, Alexis M ^a,b,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b INSERM   (France)

^c UNIVERSIDAD ANDRÉS BELLO   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BMS 936559; CD2 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GRANZYME; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; IPILIMUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MDX 1105 01; MEMBRANE PROTEIN; MK 3475; MONOCLONAL ANTIBODY; NIVOLUMAB; PERFORIN; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; TGN 1412; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA; TRX 518; UNCLASSIFIED DRUG; URELUMAB; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE RELEASE; HUMAN; IMMUNOLOGICAL SYNAPSE; INNATE IMMUNITY; LYMPHOCYTOTOXICITY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; CELL COMMUNICATION; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; SOLUBILITY; TUMOR ESCAPE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CELL COMMUNICATION; HUMANS; IMMUNITY; IMMUNOLOGICAL SYNAPSES; IMMUNOTHERAPY; MEMBRANE PROTEINS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; SOLUBILITY; T-LYMPHOCYTES; TUMOR ESCAPE;

MLCS; MLOWN;

EID: 84875426061     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/450291     Document Type: Review

References (273)

1. Bueno S. M., González P. A., Riedel C. A., Carreño L. J., Vásquez A. E., Kalergis A. M., Local cytokine response upon respiratory syncytial virus infection. Immunology Letters 2011 136 2 122 129 2-s2.0-79953026337 10.1016/j.imlet.2010.12.003
2. González P. A., Prado C. E., Leiva E. D., Carreño L. J., Bueno S. M., Riedel C. A., Kalergis A. M., Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2008 105 39 14999 15004 2-s2.0-54449084181 10.1073/pnas.0802555105
3. López M. N., Pereda C., Ramírez M., Mendoza-Naranjo A., Serrano A., Ferreira A., Poblete R., Kalergis A. M., Kiessling R., Salazar-Onfray F., Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy. Investigative Ophthalmology and Visual Science 2007 48 3 1219 1227 2-s2.0-34047246838 10.1167/iovs.06-0090 (Pubitemid 351261417)
4. Bueno S. M., González P. A., Schwebach J. R., Kalergis A. M., T cell immunity evasion by virulent Salmonella enterica. Immunology Letters 2007 111 1 14 20 2-s2.0-34347366146 10.1016/j.imlet.2007.05.003 (Pubitemid 47017478)
5. Tobar J. A., Carreño L. J., Bueno S. M., González P. A., Mora J. E., Quezada S. A., Kalergis A. M., Virulent Salmonella enterica serovar typhimurium evades adaptive immunity by preventing dendritic cells from activating T cells. Infection and Immunity 2006 74 11 6438 6448 2-s2.0-33750476332 10.1128/IAI.00063-06 (Pubitemid 44657426)
6. Llanos C., Carreño L. J., Kalergis A. M., Contribution of dendritic cell/T cell interactions to triggering and maintaining autoimmunity. Biological Research 2011 44 1 53 61 2-s2.0-79957932100 10.4067/S0716-97602011000100007
7. Carreño L. J., González P. A., Bueno S. M., Riedel C. A., Kalergis A. M., Modulation of the dendritic cell-T-cell synapse to promote pathogen immunity and prevent autoimmunity. Immunotherapy 2011 3 4 6 11 2-s2.0-79955614515 10.2217/imt.11.38
8. Iruretagoyena M. I., Riedel C. A., Leiva E. D., Gutiérrez M. A., Jacbobelli S. H., Kalergis A. M., Activating and inhibitory Fc γ receptors can differentially module T cell-mediated autoimmunity. European Journal of Immunology 2008 38 8 2241 2250 2-s2.0-51149098356 10.1002/eji.200838197
9. González P. A., Carreño L. J., Figueroa C. A., Kalergis A. M., Modulation of immunological synapse by membrane-bound and soluble ligands. Cytokine and Growth Factor Reviews 2007 18 1-2 19 31 2-s2.0-33947123684 10.1016/j.cytogfr.2007.01.003 (Pubitemid 46401428)
10. Carreño L. J., González P. A., Kalergis A. M., Modulation of T cell function by TCR/pMHC binding kinetics. Immunobiology 2006 211 1-2 47 64 2-s2.0-31444432986 10.1016/j.imbio.2005.09.003 (Pubitemid 43150108)
11. González P. A., Carreño L. J., Coombs D., Mora J. E., Palmieri E., Goldstein B., Nathenson S. G., Kalergis A. M., T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proceedings of the National Academy of Sciences of the United States of America 2005 102 13 4824 4829 2-s2.0-16344370564 10.1073/pnas.0500922102 (Pubitemid 40471538)
12. Kalergis A. M., Modulation of T cell immunity by TCR/pMHC dwell time and activating/inhibitory receptor pairs on the antigen-presenting cell. Current Pharmaceutical Design 2003 9 3 233 244 2-s2.0-0037242815 10.2174/ 1381612033392062 (Pubitemid 36131717)
13. Thomson C. T., Kalergis A. M., Sacchettini J. C., Nathenson S. G., A structural difference limited to one residue of the antigenic peptide can profoundly alter the biological outcome of the TCR-peptide/MHC class I interaction. Journal of Immunology 2001 166 6 3994 3997 2-s2.0-0035869451 (Pubitemid 32224927)
14. Kalergis A. M., Boucheron N., Doucey M. A., Palmieri E., Goyarts E. C., Vegh Z., Luescher I. F., Nathenson S. G., Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nature Immunology 2001 2 3 229 234 2-s2.0-0035286588 10.1038/85286 (Pubitemid 33705999)
15. Kalergis A. M., Nathenson S. G., Altered peptide ligand-mediated TCR antagonism can be modulated by a change in a single amino acid residue within the CDR3 β of an MHC class I- restricted TCR. Journal of Immunology 2000 165 1 280 285 2-s2.0-0034235460 (Pubitemid 30429517)
16. + cytotoxic lymphocyte population. Journal of Immunology 1999 162 12 7263 7270 2-s2.0-0033564254 (Pubitemid 29277699)
17. Wang F., Ono T., Kalergis A. M., Zhang W., DiLorenzo T. P., Lim K., Nathenson S. G., On defining the rules for interactions between the T cell receptor and its ligand: a critical role for a specific amino acid residue of the T cell receptor β chain. Proceedings of the National Academy of Sciences of the United States of America 1998 95 9 5217 5222 2-s2.0-0032574783 10.1073/pnas.95.9.5217 (Pubitemid 28208578)
18. Ono T., DiLorenzo T. P., Wang F., Kalergis A. M., Nathenson S. G., Alterations in TCR-MHC contacts subsequent to cross-recognition of class I MHC and singly substituted peptide variants. Journal of Immunology 1998 161 10 5454 5463 2-s2.0-0032533473 (Pubitemid 28519108)
19. Goyarts E. C., Vegh Z., Kalergis A. M., Hörig H., Papadopoulos N. J., Young A. C. M., Thomson C. T., Chang H. C., Joyce S., Nathenson S. G., Point mutations in the β chain CDR3 can alter the T cell receptor recognition pattern on an MHC class I/peptide complex over a broad interface area. Molecular Immunology 1998 35 10 593 607 2-s2.0-0031732229 10.1016/S0161-5890(98)00056-X (Pubitemid 28484990)
20. Grakoui A., Bromley S. K., Sumen C., Davis M. M., Shaw A. S., Allen P. M., Dustin M. L., The immunological synapse: a molecular machine controlling T cell activation. Science 1999 285 5425 221 227 2-s2.0-0033538574 10.1126/science.285.5425.221 (Pubitemid 29329988)
21. Tseng S. Y., Waite J. C., Liu M., Vardhana S., Dustin M. L., T cell-dendritic cell immunological synapses contain TCR-dependent CD28-CD80 clusters that recruit protein kinase C θ Journal of Immunology 2008 181 7 4852 4863 2-s2.0-58149280838
22. Eissmann P., Davis D. M., Inhibitory and regulatory immune synapses. Current Topics in Microbiology and Immunology 2010 340 1 63 79 2-s2.0-77950876856 10.1007/978-3-642-03858-7-4
23. Carreño L. J., Riquelme E. M., González P. A., Espagnolle N., Riedel C. A., Valitutti S., Kalergis A. M., T-cell antagonism by short half-life pMHC ligands can be mediated by an efficient trapping of T-cell polarization toward the APC. Proceedings of the National Academy of Sciences of the United States of America 2010 107 1 210 215 2-s2.0-76249118428 10.1073/pnas.0911258107
24. Thoulouze M. I., Sol-Foulon N., Blanchet F., Dautry-Varsat A., Schwartz O., Alcover A., Human immunodeficiency virus type-1 infection impairs the formation of the immunological synapse. Immunity 2006 24 5 547 561 2-s2.0-33646552033 10.1016/j.immuni.2006.02.016 (Pubitemid 43728159)
25. Friedl P., den Boer A. T., Gunzer M., Tuning immune responses: diversity and adaptation of the immunological synapse. Nature Reviews Immunology 2005 5 7 532 545 2-s2.0-21844440052 10.1038/nri1647 (Pubitemid 40961331)
26. Depoil D., Zaru R., Guiraud M., Chauveau A., Harriague J., Bismuth G., Utzny C., Müller S., Valitutti S., Immunological synapses are versatile structures enabling selective T cell polarization. Immunity 2005 22 2 185 194 2-s2.0-13844296663 10.1016/j.immuni.2004.12.010 (Pubitemid 40255710)
27. Hornsby P. J., Cellular aging and cancer. Critical Reviews in Oncology/Hematology 2011 79 2 189 195 2-s2.0-79960187460 10.1016/j.critrevonc. 2010.07.011
28. Rui L., Schmitz R., Ceribelli M., Staudt L. M., Malignant pirates of the immune system. Nature Immunology 2011 12 933 940 10.1038/ni.2094
29. Umansky V., Sevko A., Melanoma-induced immunosuppression and its neutralization. Seminars in Cancer Biology 2012 22 319 326 10.1016/j.semcancer. 2012.02.003
30. Jia J., Cui J., Liu X., Han J., Yang S., Wei Y., Chen Y., Genome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition. Molecular Immunology 2009 46 8-9 1824 1829 2-s2.0-64149120251 10.1016/j.molimm.2009.01.019
31. Stuge T. B., Holmes S. P., Saharan S., Tuettenberg A., Roederer M., Weber J. S., Lee P. P., Diversity and recognition efficiency of T cell responses to cancer. PLoS Medicine 2004 1 2, article e28 2-s2.0-15744381854 10.1371/journal.pmed.0010028 (Pubitemid 40418868)
32. Khong H. T., Restifo N. P., Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nature Immunology 2002 3 11 999 1005 2-s2.0-0036852191 10.1038/ni1102-999 (Pubitemid 35363649)
33. Itakura E., Huang R. R., Wen D. R., Paul E., Wünsch P. H., Cochran A. J., IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Modern Pathology 2011 24 6 801 809 2-s2.0-79957884105 10.1038/modpathol.2011.5
34. Martin-Orozco N., Li Y., Wang Y., Liu S., Hwu P., Liu Y. J., Dong C., Radvanyi L., Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Research 2010 70 23 9581 9590 2-s2.0-78649941232 10.1158/0008-5472.CAN-10-1379
35. Li F., Yang D., Wang Y., Liu B., Deng Y., Wang L., Shang X., Tong W., Ni B., Wu Y., Identification and modification of an HLA-A0201-restricted cytotoxic T lymphocyte epitope from Ran antigen. Cancer Immunology, Immunotherapy 2009 58 12 2039 2049 2-s2.0-65449185498 10.1007/s00262-009-0712-9
36. González H. E., Leiva A., Tobar H., Böhmwald K., Tapia G., Torres J., Mosso L. M., Bueno S. M., Gonzalez P., Kalergis A. M., Riedel C. A., Altered chemokine receptor expression in papillary thyroid cancer. Thyroid 2009 19 9 957 965 2-s2.0-70349117750 10.1089/thy.2008.0432
37. Topfer K., Kempe S., Muller N., Schmitz M., Bachmann M., Cartellieri M., Schackert G., Temme A., Tumor evasion from T cell surveillance. Journal of Biomedicine and Biotechnology 2011 2011 19 918471 10.1155/2011/918471
38. Garcia-Lora A., Algarra I., Garrido F., MHC class I antigens, immune surveillance, and tumor immune escape. Journal of Cellular Physiology 2003 195 3 346 355 2-s2.0-0038069515 10.1002/jcp.10290 (Pubitemid 36529863)
39. Fuertes M. B., Girart M. V., Molinero L. L., Domaica C. I., Rossi L. E., Barrio M. M., Mordoh J., Rabinovich G. A., Zwirner N. W., Intracellular retention of the NKG2D ligand MHC class i chain-related gene a in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. Journal of Immunology 2008 180 7 4606 4614 2-s2.0-44449119045
40. Saikali S., Avril T., Collet B., Hamlat A., Bansard J. Y., Drenou B., Guegan Y., Quillien V., Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R 2, gp100 and TRP-2 for immunotherapy. Journal of Neuro-Oncology 2007 81 2 139 148 2-s2.0-33845698912 10.1007/s11060-006-9220-3 (Pubitemid 44963972)
41. Ercolini A. M., Machiels J. P. H., Chen Y. C., Slansky J. E., Giedlen M., Reilly R. T., Jaffee E. M., Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. Journal of Immunology 2003 170 8 4273 4280 2-s2.0-0037446542 (Pubitemid 36428195)
42. Chow M. T., Moller A., Smyth M. J., Inflammation and immune surveillance in cancer. Seminars in Cancer Biology 2012 22 23 32 10.1016/j.semcancer.2011.12. 004
43. Ng P. P., Jia M., Patel K. G., Brody J. D., Swartz J. R., Levy S., Levy R., A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. Proceedings of the National Academy of Sciences of the United States of America 2012 109 36 14526 14531 10.1073/pnas.1211018109
44. Maloney D. G., Grillo-López A. J., White C. A., Bodkin D., Schilder R. J., Neidhart J. A., Janakiraman N., Foon K. A., Liles T. M., Dallaire B. K., Wey K., Royston I., Davis T., Levy R., IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997 90 6 2188 2195 2-s2.0-1842368507 (Pubitemid 27392702)
45. + T cells. The Journal of Immunology 2012 189 6 3249 3259
46. Vesely M. D., Kershaw M. H., Schreiber R. D., Smyth M. J., Natural innate and adaptive immunity to cancer. Annual Review of Immunology 2011 29 235 271 2-s2.0-79953059789 10.1146/annurev-immunol-031210-101324
47. Stevanovic S., Identification of tumour-associated T-cell epitopes for vaccine development. Nature Reviews Cancer 2002 2 7 514 520 2-s2.0-0036631492 (Pubitemid 37336518)
48. Svane I. M., Boesen M., Engel A. M., The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors-Lessons from normal and immunodeficient mice. Medical Oncology 1999 16 4 223 238 2-s2.0-0033393224 (Pubitemid 30055711)
49. + T lymphocytes: a critical component of antitumor immunity. Cancer Investigation 2005 23 5 413 419 2-s2.0-24944476490 10.1081/CNV-67428 (Pubitemid 41324359)
50. Riquelme E., Carreño L. J., González P. A., Kalergis A. M., The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity. European Journal of Immunology 2009 39 8 2259 2269 2-s2.0-70249131174 10.1002/eji.200939341
51. Kalergis A. M., Ravetch J. V., Inducing tumor immunity through the selective engagement of activating Fc γ receptors on dendritic cells. Journal of Experimental Medicine 2002 195 12 1653 1659 2-s2.0-0037124367 10.1084/jem.20020338 (Pubitemid 34666079)
52. + T cells. Journal of Immunology 2001 167 8 4276 4285 2-s2.0-0035887895 (Pubitemid 32954302)
53. Kalergis A. M., Goyarts E. C., Palmieri E., Honda S., Zhang W., Nathenson S. G., A simplified procedure for the preparation of MHC/peptide tetramers: chemical biotinylation of an unpaired cysteine engineered at the C-terminus of MHC-I. Journal of Immunological Methods 2000 234 1-2 61 70 2-s2.0-0033951457 10.1016/S0022-1759(99)00215-X (Pubitemid 30084799)
54. Röhn T. A., Reitz A., Paschen A., Nguyen X. D., Schadendorf D., Vogt A. B., Kropshofer H., A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Research 2005 65 21 10068 10078 2-s2.0-27544435777 10.1158/0008-5472.CAN-05-1973 (Pubitemid 41541489)
55. McIntyre B. W., Allison J. P., The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell 1983 34 3 739 746 2-s2.0-0020593643 (Pubitemid 13023344)
56. Ishiguro N., Tanaka A., Shinagawa M., Sequence analysis of bovine T-cell receptor chain. Immunogenetics 1990 31 1 57 60 2-s2.0-0025057169 10.1007/BF00702490 (Pubitemid 20034241)
57. Tanaka A., Ishiguro N., Shinagawa M., Sequence and diversity of bovine T-cell receptor β -chain genes. Immunogenetics 1990 32 4 263 271 2-s2.0-0025066253 (Pubitemid 20370379)
58. Bentley G. A., Mariuzza R. A., The structure of the T cell antigen receptor. Annual Review of Immunology 1996 14 563 590 2-s2.0-0029935523 10.1146/annurev.immunol.14.1.563 (Pubitemid 26130195)
59. Davis M. M., Bjorkman P. J., T-cell antigen receptor genes and T-cell recognition. Nature 1988 334 395 402 10.1038/334395a0
60. + T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells. Cancer Immunology, Immunotherapy 2012 62 2 257 271
61. + cytotoxic T lymphocytes in the control of viral diseases and cancer. International Reviews of Immunology 2010 29 4 371 402 2-s2.0-77954789175 10.3109/08830185.2010.489658
62. + T cells in viral immunity. Expert Review of Vaccines 2010 9 12 1453 1463 2-s2.0-78649510318 10.1586/erv.10.132
63. + T cells in viral immunity. The Journal of Experimental Medicine 2012 209 1391 1395 10.1084/jem.20121517
64. + T cells for the treatment of EBV-related tumors. Journal of Immunology 2010 184 10 5895 5902 2-s2.0-77954722311 10.4049/jimmunol.0902850
65. Reiner S. L., Development in motion: helper T cells at work. Cell 2007 129 1 33 36 2-s2.0-33947720523 10.1016/j.cell.2007.03.019 (Pubitemid 46507593)
66. + T cells. Current Opinion in Immunology 2009 21 2 200 208 2-s2.0-65249126905 10.1016/j.coi.2009.02.004
67. Rajkovic I., Dragicevic A., Vasilijic S., Bozic B., Dzopalic T., Tomic S., Majstorovic I., Vucevic D., Djokic J., Balint B., Colic M., Differences in T-helper polarizing capability between human monocyte-derived dendritic cells and monocyte-derived Langerhans'-like cells. Immunology 2011 132 217 225 10.1111/j.1365-2567.2010.03356.x
68. Kalinski P., Wieckowski E., Muthuswamy R., de Jong E., Generation of stable Th1/CTL-, Th2-, and Th17-inducing human dendritic cells. Methods in Molecular Biology 2010 595 117 133 2-s2.0-75549083184
69. Wan Y. Y., Flavell R. A., How diverse-CD4 effector T cells and their functions. Journal of Molecular Cell Biology 2009 1 1 20 36 2-s2.0-77449090327 10.1093/jmcb/mjp001
70. Brennan A. J., Chia J., Trapani J. A., Voskoboinik I. Perforin deficiency and susceptibility to cancer. Cell Death & Differentiation 2010 17 607 615
71. Cullen S. P., Brunet M., Martin S. J., Granzymes in cancer and immunity. Cell Death and Differentiation 2010 17 4 616 623 2-s2.0-77949497729 10.1038/cdd.2009.206
72. Pipkin M. E., Lieberman J., Delivering the kiss of death: progress on understanding how perforin works. Current Opinion in Immunology 2007 19 3 301 308 2-s2.0-34247577498 10.1016/j.coi.2007.04.011 (Pubitemid 46687016)
73. Stinchcombe J. C., Bossi G., Booth S., Griffiths G. M., The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 2001 15 5 751 761 2-s2.0-0035655587 10.1016/S1074-7613(01)00234-5 (Pubitemid 34008503)
74. Jenkins M. R., Griffiths G. M., The synapse and cytolytic machinery of cytotoxic T cells. Current Opinion in Immunology 2010 22 3 308 313 2-s2.0-77953545815 10.1016/j.coi.2010.02.008
75. Debatin K. M., Krammer P. H., Death receptors in chemotherapy and cancer. Oncogene 2004 23 16 2950 2966 2-s2.0-2342453921 10.1038/sj.onc.1207558 (Pubitemid 38638855)
76. Bossi G., Griffiths G. M., Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nature Medicine 1999 5 1 90 96 2-s2.0-0032974475 10.1038/4779 (Pubitemid 29051004)
77. Norcross M. A., A synaptic basis for T-lymphocyte activation. Annual Review of Immunology 1984 135 113 134 (Pubitemid 14024063)
78. Monks C. R. F., Freiberg B. A., Kupfer H., Sciaky N., Kupfer A., Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998 395 6697 82 86 2-s2.0-0032480279 10.1038/25764 (Pubitemid 28420234)
79. Dustin M. L., Olszowy M. W., Holdorf A. D., Li J., Bromley S., Desai N., Widder P., Rosenberger F., van der Merwe P. A., Allen P. M., Shaw A. S., A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell 1998 94 5 667 677 2-s2.0-0032483559 10.1016/S0092-8674(00) 81608-6 (Pubitemid 28427585)
80. Davis D. M., Dustin M. L., What is the importance of the immunological synapse? Trends in Immunology 2004 25 6 323 327 2-s2.0-2342566929 10.1016/j.it.2004.03.007 (Pubitemid 38610356)
81. Jenkins M. R., Tsun A., Stinchcombe J. C., Griffiths G. M., The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse. Immunity 2009 31 4 621 631 2-s2.0-70349751653 10.1016/j.immuni.2009.08.024
82. + T-cell synapses involve multiple distinct stages. Proceedings of the National Academy of Sciences of the United States of America 2011 108 17099 17104 10.1073/pnas.1113703108
83. Stinchcombe J. C., Salio M., Cerundolo V., Pende D., Arico M., Griffiths G. M., Centriole polarisation to the immunological synapse directs secretion from cytolytic cells of both the innate and adaptive immune systems. BMC Biology 2011 9, article 45 2-s2.0-79959574557 10.1186/1741-7007-9-45
84. Krummel M. F., Sjaastad M. D., Wulfing C. W., Davis M. M., Differential clustering of CD4 and CD3 ζ during T cell recognition. Science 2000 289 5483 1349 1352 2-s2.0-0034714184 10.1126/science.289.5483.1349 (Pubitemid 30656051)
85. Wülfing C., Davis M. M., A receptor/cytoskeletal movement triggered by costimulation during T cell activation. Science 1998 282 5397 2266 2269 2-s2.0-0032545218 10.1126/science.282.5397.2266 (Pubitemid 29004077)
86. Alarcón B., Mestre D., Martínez-Martín N., The immunological synapse: a cause or consequence of T-cell receptor triggering? Immunology 2011 133 4 420 425 2-s2.0-79959906941 10.1111/j.1365-2567.2011.03458. x
87. Delon J., Kaibuchi K., Germain R. N., Exclusion of CD43 from the immunological synapce is mediated by phosphorylation-regulated relocation of the cytoskeletal adaptor Moesin. Immunity 2001 15 5 691 701 2-s2.0-0035652354 10.1016/S1074-7613(01)00231-X (Pubitemid 34008498)
88. van der Merwe P. A., Davis S. J., Shaw A. S., Dustin M. L., Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. Seminars in Immunology 2000 12 1 5 21 2-s2.0-0034005120 10.1006/smim.2000.0203 (Pubitemid 30114012)
89. Hegde V. L., Singh N. P., Nagarkatti P. S., Nagarkatti M., CD44 mobilization in allogeneic dendritic cell-T cell immunological synapse plays a key role in T cell activation. Journal of Leukocyte Biology 2008 84 1 134 142 2-s2.0-46949103997 10.1189/jlb.1107752 (Pubitemid 351960288)
90. van der Merwe P. A., Formation and function of the immunological synapse. Current Opinion in Immunology 2002 14 3 293 298 2-s2.0-0036604984 10.1016/S0952-7915(02)00350-3 (Pubitemid 34327969)
91. Law B. J., Langley J. M., Allen U., Paes B., Lee D. S. C., Mitchell I., Sampalis J., Walti H., Robinson J., O'Brien K., Majaesic C., Caouette G., Frenette L., Le Saux N., Simmons B., Moisiuk S., Sankaran K., Ojah C., Singh A. J., Lebel M. H., Bacheyie G. S., Onyett H., Michaliszyn A., Manzi P., Parison D., The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatric Infectious Disease Journal 2004 23 9 806 814 2-s2.0-6344278290 10.1097/01.inf.0000137568.71589.bd (Pubitemid 40221021)
92. Leupin O., Zaru R., Laroche T., Müller S., Valitutti S., Exclusion of CD45 from the T-cell receptor signaling area in antigen-stimulated T lymphocytes. Current Biology 2000 10 5 277 280 2-s2.0-0034624809 10.1016/S0960-9822(00)00362-6 (Pubitemid 30152951)
93. Wild M. K., Cambiaggi A., Brown M. H., Davies E. A., Ohno H., Saito T., van der Merwe P. A., Dependence of T cell antigen recognition on the dimensions of an accessory receptor-ligand complex. Journal of Experimental Medicine 1999 190 1 31 41 2-s2.0-0033526773 10.1084/jem.190.1.31 (Pubitemid 29330121)
94. Valitutti S., Dessing M., Aktories K., Gallati H., Lanzavecchia A., Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. Journal of Experimental Medicine 1995 181 2 577 584 2-s2.0-0028961573 10.1084/jem.181.2.577
95. Belay E. D., Holman R. C., Maddox R. A., Foster D. A., Schonberger L. B., Kawasaki syndrome hospitalizations and associated costs in the United States. Public Health Reports 2003 118 5 464 469 2-s2.0-0042822273 (Pubitemid 37059480)
96. Weiss A., Shields R., Newton M., Ligand-receptor interactions required for commitment to the activation of the interleukin 2 gene. Journal of Immunology 1987 138 7 2169 2176 2-s2.0-0023156442 (Pubitemid 17046269)
97. Davis M. M., Krogsgaard M., Huppa J. B., Sumen C., Purbhoo M. A., Irvine D. J., Wu L. C., Ehrlich L., Dynamics of cell surface molecules during T cell recognition. Annual Review of Biochemistry 2003 72 717 742 2-s2.0-0043268924 10.1146/annurev.biochem.72.121801.161625 (Pubitemid 36930458)
98. Bastien N., Ward D., van Caeseele P., Brandt K., Lee S. H. S., McNabb G., Klisko B., Chan E., Li Y., Human metapneumovirus infection in the Canadian population. Journal of Clinical Microbiology 2003 41 10 4642 4646 2-s2.0-0141889253 10.1128/JCM.41.10.4642-4646.2003 (Pubitemid 37259770)
99. Cahalan M. D., Parker I., Wei S. H., Miller M. J., Two-photon tissue imaging: seeing the immune system in a fresh light. Nature Reviews Immunology 2002 2 11 872 880 2-s2.0-0036831870 10.1038/nri935 (Pubitemid 37328709)
100. Molon B., Gri G., Bettella M., Gómez-Moutón C., Lanzavecchia A., Martínez-A C., Mañes S., Viola A., T cell costimulation by chemokine receptors. Nature Immunology 2005 6 5 465 471 2-s2.0-18244389686 10.1038/ni1191 (Pubitemid 41716759)
101. Maldonade R. A., Irvine D. J., Schreiber R., Glimcher L. H., A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature 2004 431 7008 527 532 2-s2.0-4944266186 10.1038/nature02916 (Pubitemid 39336325)
102. Bonasio R., Scimone M. L., Schaerli P., Grabie N., Lichtman A. H., von Andrian U. H., Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nature Immunology 2006 7 10 1092 1100 2-s2.0-33748866909 10.1038/ni1385 (Pubitemid 44420654)
103. Wülfing C., Sumen C., Sjaastad M. D., Wu L. C., Dustin M. L., Davis M. M., Costimulation and endogenous MHC ligands contribute to T cell recognition. Nature Immunology 2002 3 1 42 47 2-s2.0-0036141994 10.1038/ni741 (Pubitemid 34065616)
104. Dustin M. L., T-cell activation through immunological synapses and kinapses. Immunological Reviews 2008 221 1 77 89 2-s2.0-38949197102 10.1111/j.1600-065X.2008.00589.x (Pubitemid 351230116)
105. Huppa J. B., Gleimer M., Sumen C., Davis M. M., Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nature Immunology 2003 4 8 749 755 2-s2.0-0041695164 10.1038/ni951 (Pubitemid 36986758)
106. Fukumoto R., Dundr M., Nicot C., Adams A., Valeri V. W., Samelson L. E., Franchini G., Inhibition of T-cell receptor signal transduction and viral expression by the linker for activation of T cells-interacting p12I protein of human T-cell leukemia/lymphoma virus type 1. Journal of Virology 2007 81 17 9088 9099 2-s2.0-34548158644 10.1128/JVI.02703-06 (Pubitemid 47311452)
107. Chi B., Dickensheets H. L., Spann K. M., Alston M. A., Luongo C., Dumoutier L., Huang J., Renauld J. C., Kotenko S. V., Roederer M., Beeler J. A., Donnelly R. P., Collins P. L., Rabin R. L., Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. Journal of Virology 2006 80 10 5032 5040 2-s2.0-33646451493 10.1128/JVI.80.10.5032-5040.2006
108. Mustelin T., Taskén K., Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochemical Journal 2003 371 1 15 27 2-s2.0-0037392883 10.1042/BJ20021637 (Pubitemid 36458075)
109. Bunnell S. C., Hong D. I., Kardon J. R., Yamazaki T., McGlade C. J., Barr V. A., Samelson L. E., T cell receptor ligation induces the formation of dynamically regulated signaling assemblies. Journal of Cell Biology 2002 158 7 1263 1275 2-s2.0-0037144842 10.1083/jcb.200203043
110. + T cells. Clinical and Experimental Immunology 1992 88 3 527 536 2-s2.0-0026780401
111. Armstrong D., Grimwood K., Carlin J. B., Carzino R., Hull J., Olinsky A., Phelan P. D., Severe viral respiratory infections in infants with cystic fibrosis. Pediatric Pulmonology 1998 26 371 379 (Pubitemid 29024978)
112. Irving B. A., Chan A. C., Weiss A., Functional characterization of a signal transducing motif present in the T cell antigen receptor ζ chain. Journal of Experimental Medicine 1993 177 4 1093 1103 2-s2.0-0027399703 (Pubitemid 23097398)
113. Iwashima M., Kinetic perspectives of T cell antigen receptor signaling: a two-tier model for T cell full activation. Immunological Reviews 2003 191 196 210 2-s2.0-0037306145 10.1034/j.1600-065X.2003.00024.x (Pubitemid 36398858)
114. Wange R. L., Tony Kong A. N., Samelson L. E., A tyrosine-phosphorylated 70-kDa protein binds a photoaffinity analogue of ATP and associates with both the ζ chain and CD3 components of the activated T cell antigen receptor. Journal of Biological Chemistry 1992 267 17 11685 11688 2-s2.0-0026752591
115. Yokosuka T., Saito T., The immunological synapse, TCR microclusters, and T cell activation. Current Topics in Microbiology and Immunology 2010 340 1 81 107 2-s2.0-77950881648 10.1007/978-3-642-03858-7-5
116. Yokosuka T., Sakata-Sogawa K., Kobayashi W., Hiroshima M., Hashimoto-Tane A., Tokunaga M., Dustin M. L., Saito T., Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76. Nature Immunology 2005 6 12 1253 1262 2-s2.0-30044441433 10.1038/ni1272 (Pubitemid 43045637)
117. Varma R., Campi G., Yokosuka T., Saito T., Dustin M. L., T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. Immunity 2006 25 1 117 127 2-s2.0-33746011209 10.1016/j.immuni.2006.04.010 (Pubitemid 44066825)
118. Harding F. A., McArthur J. G., Gross J. A., Raulet D. H., Allison J. P., CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992 356 6370 607 609 2-s2.0-0026537347 10.1038/356607a0
119. Lenschow D. J., Walunas T. L., Bluestone J. A., CD28/B7 system of T cell costimulation. Annual Review of Immunology 1996 14 233 258 2-s2.0-0029944533 10.1146/annurev.immunol.14.1.233 (Pubitemid 26130184)
120. + T cells is required for optimal antigen-dependent activation in vivo. Journal of Immunology 2004 173 7 4443 4451 2-s2.0-4644312322 (Pubitemid 39280674)
121. Chirathaworn C., Kohlmeier J. E., Tibbetts S. A., Rumsey L. M., Chan M. A., Benedict S. H., Stimulation through intercellular adhesion molecule-1 provides a second signal for T cell activation. Journal of Immunology 2002 168 11 5530 5537 2-s2.0-0036604304 (Pubitemid 34556132)
122. Grewal I. S., Flavell R. A., CD40 and CD154 in cell-mediated immunity. Annual Review of Immunology 1998 16 111 135 2-s2.0-0031944607 10.1146/annurev.immunol.16.1.111 (Pubitemid 28183361)
123. Acuto O., Michel F., CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nature Reviews Immunology 2003 3 12 939 951 2-s2.0-0347505003 (Pubitemid 37521536)
124. Harris N. L., Ronchese F., The role of B7 costimulation in T-cell immunity. Immunology and Cell Biology 1999 77 4 304 311 2-s2.0-0032807417 10.1046/j.1440-1711.1999.00835.x (Pubitemid 29370100)
125. Redmond W. L., Ruby C. E., Weinberg A. D., The Role of OX40-mediated Co-stimulation in T-cell activation and survival. Critical Reviews in Immunology 2009 29 3 187 201 2-s2.0-67650290300
126. + T cell acquisition of the bystander pMHC I colocalizing in the same immunological synapse comprising pMHC II and costimulatory CD40, CD54, CD80, OX40L, and 41BBL. Biochemical and Biophysical Research Communications 2007 362 4 822 828 2-s2.0-34548573256 10.1016/j.bbrc.2007.08.072 (Pubitemid 47390647)
127. + T cells. Trends in Immunology 2002 23 8 378 380 2-s2.0-0036679629 10.1016/S1471-4906(02)02263-9 (Pubitemid 34804627)
128. Vinay D. S., Kwon B. S., Role of 4-1BB in immune responses. Seminars in Immunology 1998 10 6 481 489 2-s2.0-0032374052 10.1006/smim.1998.0157 (Pubitemid 28564377)
129. Schaer D. A., Murphy J. T., Wolchok J. D., Modulation of GITR for cancer immunotherapy. Current Opinion in Immunology 2012 24 217 224 10.1016/j.coi.2011.12.011
130. Rogers P. R., Song J., Gramaglia I., Killeen N., Croft M., OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001 15 3 445 455 2-s2.0-0034812971 10.1016/S1074-7613(01)00191- 1 (Pubitemid 32907391)
131. Weatherill A. R., Maxwell J. R., Takahashi C., Weinberg A. D., Vella A. T., OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo. Cellular Immunology 2001 209 1 63 75 2-s2.0-0035836411 10.1006/cimm.2001.1783 (Pubitemid 32568567)
132. Holdorf A. D., Kanagawa O., Shaw A. S., CD28 and T cell co-stimulation. Reviews in Immunogenetics 2000 2 2 175 184 2-s2.0-0033772368
133. + T cells in induced by IL-2 receptor γ chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis. International Immunology 2000 12 7 1005 1013 2-s2.0-0033859430 (Pubitemid 30601367)
134. Habib-Agahi M., Phan T. T., Searle P. F., Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. International Immunology 2007 19 12 1383 1394 2-s2.0-36248951128 10.1093/intimm/dxm106 (Pubitemid 350131344)
135. + regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 2008 105 27 9331 9336 2-s2.0-48249147441 10.1073/pnas.0710441105
136. Brown J. A., Dorfman D. M., Ma F. R., Sullivan E. L., Munoz O., Wood C. R., Greenfield E. A., Freeman G. J., Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. Journal of Immunology 2003 170 3 1257 1266 2-s2.0-0037307930 (Pubitemid 36139491)
137. Latchman Y., Wood C. R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A. J., Brown J. A., Nunes R., Greenfield E. A., Bourque K., Boussiotis V. A., Carter L. L., Carreno B. M., Malenkovich N., Nishimura H., Okazaki T., Honjo T., Sharpe A. H., Freeman G. J., PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology 2001 2 3 261 268 2-s2.0-5844264920 10.1038/85330 (Pubitemid 33706004)
138. Tuettenberg A., Huter E., Hubo M., Horn J., Knop J., Grimbacher B., Kroczek R. A., Stoll S., Jonuleit H., The role of ICOS in directing T cell responses: ICOS-dependent induction of T cell anergy by tolerogenic dendritic cells. Journal of Immunology 2009 182 6 3349 3356 2-s2.0-65449156015 10.4049/jimmunol.0802733
139. Greenwald R. J., Boussiotis V. A., Lorsbach R. B., Abbas A. K., Sharpe A. H., CTLA-4 regulates induction of anergy in vivo. Immunity 2001 14 2 145 155 2-s2.0-0035102196 (Pubitemid 32206517)
140. + regulatory T cells conveying respiratory tolerance. The Journal of Immunology 2012 189 1975 1982 10.4049/jimmunol.1103581
141. Avril T., Saikali S., Vauleon E., Jary A., Hamlat A., De Tayrac M., Mosser J., Quillien V., Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. Journal of Neuroimmunology 2010 225 1-2 22 33 2-s2.0-77955665451 10.1016/j.jneuroim.2010.04.003
142. Geng L., Deng J., Jiang G., Song P., Wang Z., Jiang Z., Zhang M., Zheng S., B7-H1 up-regulated expression in human hepatocellular carcinoma tissue: correlation with tumor interleukin-10 levels. Hepatogastroenterology 2011 58 960 964
143. Hua D., Sun J., Mao Y., Chen L. J., Wu Y. Y., Zhang X. G., B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World Journal of Gastroenterology 2012 18 971 978 10.3748/wjg.v18.i9.971
144. Ghebeh H., Mohammed S., Al-Omair A., Qattan A., Lehe C., Al-Qudaihi G., Elkum N., Alshabanah M., Amer S. B., Tulbah A., Ajarim D., Al-Tweigeri T., Dermime S. D., The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006 8 3 190 198 2-s2.0-33646367200 10.1593/neo.05733 (Pubitemid 43671234)
145. Andorsky D. J., Yamada R. E., Said J., Pinkus G. S., Betting D. J., Timmerman J. M., Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clinical Cancer Research 2011 17 13 4232 4244 2-s2.0-79960318715 10.1158/1078-0432.CCR-10-2660
146. Mu C. Y., Huang J. A., Chen Y., Chen C., Zhang X. G., High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Medical Oncology 2011 28 682 688 10.1007/s12032-010-9515-2
147. Gadiot J., Hooijkaas A. I., Kaiser A. D. M., van Tinteren H., van Boven H., Blank C., Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011 117 10 2192 2201 2-s2.0-79955518331 10.1002/cncr.25747
148. Chan R. C., Xie Y., CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens. Oncology Reports 2004 12 2 435 442 2-s2.0-16544370589
149. Kronfeld K., Abken H., Seliger B., B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy. International Journal of Cancer 2005 117 5 794 799 2-s2.0-27744588820 10.1002/ijc.21230 (Pubitemid 41598831)
150. Ramsay A. G., Clear A. J., Fatah R., Gribben J. G., Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012 120 1412 1421 10.1182/blood-2012-02-411678
151. Yokosuka T., Takamatsu M., Kobayashi-Imanishi W., Hashimoto-Tane A., Azuma M., Saito T., Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. The Journal of Experimental Medicine 2012 209 1201 1217
152. + regulatory T cells is mediated by cell surface-bound transforming growth factor β Journal of Experimental Medicine 2001 194 5 629 644 2-s2.0-0035801335 10.1084/jem.194.5.629 (Pubitemid 32844773)
153. Li M. O., Sanjabi S., Flavell R., Transforming growth factor- β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006 25 3 455 471 2-s2.0-33748448717 10.1016/j.immuni.2006.07.011 (Pubitemid 44354214)
154. Li M. O., Wan Y. Y., Sanjabi S., Robertson A. K. L., Flavell R. A., Transforming growth factor- β regulation of immune responses. Annual Review of Immunology 2006 24 99 146 2-s2.0-33646164362 10.1146/annurev.immunol.24. 021605.090737
155. Gorelik L., Flavell R. A., Transforming growth factor- β in T-cell biology. Nature Reviews Immunology 2002 2 1 46 53 2-s2.0-0036372440 (Pubitemid 37328775)
156. + regulatory T cells. Journal of Leukocyte Biology 2007 81 1 144 153 2-s2.0-33845899100 10.1189/jlb.0606409 (Pubitemid 46021263)
157. Eisele G., Wischhusen J., Mittelbronn M., Meyermann R., Waldhauer I., Steinle A., Weller M., Friese M. A., TGF- β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006 129 9 2416 2425 2-s2.0-33749234357 10.1093/brain/awl205 (Pubitemid 44522126)
158. + regulatory T cell proliferation. Journal of Experimental Medicine 2005 202 7 919 929 2-s2.0-25844504654 10.1084/jem.20050463 (Pubitemid 41396892)
159. Coe D., Addey C., White M., Simpson E., Dyson J., Chai J. G., The roles of antigen-specificity, responsiveness to transforming growth factor- β and antigen-presenting cell subsets in tumour-induced expansion of regulatory T cells. Immunology 2010 131 4 556 569 2-s2.0-78149376348 10.1111/j.1365-2567. 2010.03328.x
160. Penafuerte C., Galipeau J., TGF β secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunology, Immunotherapy 2008 57 8 1197 1206 2-s2.0-44249100929 10.1007/s00262-008-0453-1
161. Thakur V. S., Shankar B., Chatterjee S., Premachandran S., Sainis K. B., Role of tumor-derived transforming growth factor- β 1 (TGF- β 1) in site-dependent tumorigenicity of murine ascitic lymphosarcoma. Cancer Immunology, Immunotherapy 2005 54 9 837 847 2-s2.0-22244469407 10.1007/s00262-004-0656-z (Pubitemid 40991326)
162. Teicher B. A., Transforming growth factor- β and the immune response to malignant disease. Clinical Cancer Research 2007 13 21 6247 6251 2-s2.0-35948933046 10.1158/1078-0432.CCR-07-1654 (Pubitemid 350075011)
163. + T cells. Journal of Immunology 1998 160 7 3188 3193 2-s2.0-0032055224 (Pubitemid 28164707)
164. Collison L. W., Workman C. J., Kuo T. T., Boyd K., Wang Y., Vignali K. M., Cross R., Sehy D., Blumberg R. S., Vignali D. A., The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007 450 566 569 10.1038/nature06306 (Pubitemid 350190247)
165. + T cells. Nature Immunology 2007 8 12 1353 1362 2-s2.0-36248976097 10.1038/ni1536 (Pubitemid 350131172)
166. Workman C. J., Vignali D. A. A., Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). Journal of Immunology 2005 174 2 688 695 2-s2.0-11844269957 (Pubitemid 40094261)
167. Huang C. T., Workman C. J., Flies D., Pan X., Marson A. L., Zhou G., Hipkiss E. L., Ravi S., Kowalski J., Levitsky H. I., Powell J. D., Pardoll D. M., Drake C. G., Vignali D. A. A., Role of LAG-3 in regulatory T cells. Immunity 2004 21 4 503 513 2-s2.0-5644263642 10.1016/j.immuni.2004.08.010 (Pubitemid 39370506)
168. Liang B., Workman C., Lee J., Chew C., Dale B. M., Colonna L., Flores M., Li N., Schweighoffer E., Greenberg S., Tybulewicz V., Vignali D., Clynes R., Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. The Journal of Immunology 2008 180 5916 5926
169. Cao X., Cai S. F., Fehniger T. A., Song J., Collins L. I., Piwnica-Worms D. R., Ley T. J., Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007 27 4 635 646 2-s2.0-35449006679 10.1016/j.immuni.2007.08.014 (Pubitemid 47628832)
170. + T cells selectively kill B lymphocytes. Blood 2006 107 10 3925 3932 2-s2.0-33646567156 10.1182/blood-2005-11-4502 (Pubitemid 43726798)
171. Romagnani S., T-cell subsets (Th1 versus Th2). Annals of Allergy, Asthma and Immunology 2000 85 1 9 21 2-s2.0-0033861859 (Pubitemid 30619408)
172. Dejana E., The transcellular railway: insights into leukocyte diapedesis. Nature Cell Biology 2006 8 2 105 107 2-s2.0-33645147349 10.1038/ncb0206-105
173. Bromley S. K., Peterson D. A., Gunn M. D., Dustin M. L., Cutting edge: hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation. Journal of Immunology 2000 165 1 15 19 2-s2.0-0034235794 (Pubitemid 30429484)
174. Bromley S. K., Dustin M. L., Stimulation of naïve T-cell adhesion and immunological synapse formation by chemokine-dependent and -independent mechanisms. Immunology 2002 106 3 289 298 2-s2.0-0036308590 10.1046/j.1365-2567. 2002.01441.x (Pubitemid 34748122)
175. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., Liu Y., Li D., Yuan Y., Zhang G. M., Feng Z. H., CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Letters 2007 252 1 86 92 2-s2.0-34248328368 10.1016/j.canlet.2006.12.012 (Pubitemid 46734559)
176. Facciabene A., Peng X., Hagemann I. S., Balint K., Barchetti A., Wang L. P., Gimotty P. A., Gilks C. B., Lal P., Zhang L., Coukos G., Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011 475 226 230 10.1038/nature10169
177. Huse M., Lillemeier B. F., Kuhns M. S., Chen D. S., Davis M. M., T cells use two directionally distinct pathways for cytokine secretion. Nature Immunology 2006 7 3 247 255 2-s2.0-33344458030 10.1038/ni1304
178. Carreño L. J., Bueno S. M., Bull P., Nathenson S. G., Kalergis A. M., The half-life of the T-cell receptor/peptide-major histocompatibility complex interaction can modulate T-cell activation in response to bacterial challenge. Immunology 2007 121 2 227 237 2-s2.0-34247519546 10.1111/j.1365-2567. 2007.02561.x (Pubitemid 46663091)
179. de Jong A., Contribution of mass spectrometry to contemporary immunology. Mass Spectrometry Reviews 1998 17 5 311 335 2-s2.0-0032152437 (Pubitemid 128628190)
180. Hunt D. F., Michel H., Dickinson T. A., Shabanowitz J., Cox A. L., Sakaguchi K., Appella E., Grey H. M., Sette A., Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-A(d). Science 1992 256 5065 1817 1820 2-s2.0-0026664454
181. Hunt D. F., Henderson R. A., Shabanowitz J., Sakaguchi K., Michel H., Sevilir N., Cox A. L., Appella E., Engelhard V. H., Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992 255 1261 1263 10.1126/science.1546328
182. Falk K., Rotzschke O., Stevanovic S., Jung G., Rammensee H. G., Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991 351 6324 290 296 2-s2.0-0025855156 10.1038/351290a0 (Pubitemid 21896578)
183. Demotz S., Grey H. M., Sette A., The minimal number of class II MHC-antigen complexes needed for T cell activation. Science 1990 249 4972 1028 1030 2-s2.0-0025182003
184. Harding C. V., Unanue E. R., Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature 1990 346 6284 574 576 2-s2.0-0025286210 10.1038/346574a0 (Pubitemid 20238811)
185. Restifo N. P., Esquivel F., Kawakami Y., Yewdell J. W., Mule J. J., Rosenberg S. A., Bennink J. R., Identification of human cancers deficient in antigen processing. Journal of Experimental Medicine 1993 177 2 265 272 2-s2.0-0027478361 (Pubitemid 23117076)
186. Kageshita T., Hirai S., Ono T., Hicklin D. J., Ferrone S., Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. American Journal of Pathology 1999 154 3 745 754 2-s2.0-0033034333 (Pubitemid 29122593)
187. Gewurz B. E., Gaudet R., Tortorella D., Wang E. W., Ploegh H. L., Wiley D. C., Antigen presentation subverted: structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. Proceedings of the National Academy of Sciences of the United States of America 2001 98 12 6794 6799 2-s2.0-0035811033 10.1073/pnas.121172898 (Pubitemid 32538296)
188. Johnson W. E., Desrosiers R. C., Viral persistence: HIV's strategies of immune system evasion. Annual Review of Medicine 2002 53 499 518 2-s2.0-0036181249 10.1146/annurev.med.53.082901.104053 (Pubitemid 34177893)
189. Tobar J. A., González P. A., Kalergis A. M., Salmonella escape from antigen presentation can be overcome by targeting bacteria to Fc γ receptors on dendritic cells. Journal of Immunology 2004 173 6 4058 4065 2-s2.0-4644333888 (Pubitemid 39280770)
190. Lorenzo M. E., Ploegh H. L., Tirabassi R. S., Viral immune evasion strategies and the underlying cell biology. Seminars in Immunology 2001 13 1 1 9 2-s2.0-0035046094 10.1006/smim.2000.0290 (Pubitemid 32304220)
191. Sykulev Y., Joo M., Vturina I., Tsomides T. J., Eisen H. N., Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996 4 6 565 571 2-s2.0-0030176270 10.1016/S1074-7613(00) 80483-5 (Pubitemid 26233310)
192. Aebischer T., Oehen S., Hengartner H., Preferential usage of V(4 and V(β)10 T cell receptor genes by lymphocytic choriomeningitis virus glycoprotein-specific H-2 Db -restricted cytotoxic T cells. European Journal of Immunology 1990 20 3 523 531 2-s2.0-0025278329 (Pubitemid 20101290)
193. Eisen H. N., Sykulev Y., Tsomides T. J., Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. Advances in Protein Chemistry 1996 49 1 56 2-s2.0-0029805829 (Pubitemid 26360374)
194. Valitutti S., Lanzavecchia A., Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Immunology Today 1997 18 6 299 304 2-s2.0-0031172162 10.1016/S0167-5699(97)01075-X (Pubitemid 27261450)
195. Valitutti S., Muller S., Cella M., Padovan E., Lanzavecchia A., Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 1995 375 6527 148 151 2-s2.0-0029037210
196. Lanzavecchia A., Sallusto F., Antigen decoding by T lymphocytes: from synapses to fate determination. Nature Immunology 2001 2 6 487 492 2-s2.0-0035377009 10.1038/88678 (Pubitemid 33705849)
197. Rachmilewitz J., Lanzavecchia A., A temporal and spatial summation model for T-cell activation: signal integration and antigen decoding. Trends in Immunology 2002 23 12 592 595 2-s2.0-0036898764 10.1016/S1471-4906(02)02342-6 (Pubitemid 35449098)
198. Davis M. M., Boniface J. J., Reich Z., Lyons D., Hampl J., Arden B., Chien Y. H., Ligand recognition by β T cell receptors. Annual Review of Immunology 1998 16 523 544 2-s2.0-17344362313 10.1146/annurev.immunol.16.1.523 (Pubitemid 28183375)
199. + T cells without selection of higher affinity TCR. Nature Immunology 2001 2 8 711 717 2-s2.0-0034889233 10.1038/90650 (Pubitemid 32747160)
200. Iruretagoyena M. I., Tobar J. A., González P. A., Sepúlveda S. E., Figueroa C. A., Burgos R. A., Hancke J. L., Kalergis A. M., Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. Journal of Pharmacology and Experimental Therapeutics 2005 312 1 366 372 2-s2.0-11844268084 10.1124/jpet.104.072512 (Pubitemid 40096490)
201. Iruretagoyena M. I., Wiesendanger M., Kalergis A. M., The dendritic cell-T cell synapse as a determinant of autoimmune pathogenesis. Current Pharmaceutical Design 2006 12 2 131 147 2-s2.0-33644850351 10.2174/ 138161206775193145
202. McKeithan T. W., Kinetic proofreading in T-cell receptor signal transduction. Proceedings of the National Academy of Sciences of the United States of America 1995 92 5042 5046 10.1073/pnas.92.11.5042
203. Savage P. A., Boniface J. J., Davis M. M., A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 1999 10 4 485 492 2-s2.0-0033118739 10.1016/S1074-7613(00)80048-5 (Pubitemid 29205484)
204. Coombs D., Kalergis A. M., Nathenson S. G., Wofsy C., Goldstein B., Activated TCR remain marked for internalization after dissociation from peptide-MHC. Nature Immunology 2002 3 926 931 10.1038/ni838 (Pubitemid 35154005)
205. Sloan-Lancaster J., Shaw A. S., Rothbard J. B., Allen P. M., Partial T cell signaling: altered phospho- ζ and lack of zap70 recruitment in APL-induced T cell anergy. Cell 1994 79 5 913 922 2-s2.0-0027967385 10.1016/0092-8674(94)90080-9 (Pubitemid 24371981)
206. Štefanová I., Hemmer B., Vergelli M., Martin R., Biddison W. E., Germain R. N., TCR ligand discrimination is enforced by competing ERK positive and SHP-I negative feedback pathways. Nature Immunology 2003 4 3 248 254 2-s2.0-0037338890 10.1038/ni895 (Pubitemid 36322134)
207. Coombs D., Kalergis A. M., Nathenson S. G., Wofsy C., Goldstein B., Activated TCRs remain marked for internalization after dissociation from pMHC. Nature Immunology 2002 3 926 931 10.1038/ni838 (Pubitemid 35154005)
208. Lau L. L., Jiang J., Shen H., In vivo modulation of T cell responses and protective immunity by TCR antagonism during infection. Journal of Immunology 2005 174 12 7970 7976 2-s2.0-20444376211 (Pubitemid 40806307)
209. + T cells by C-terminal truncation of a minimum epitope. Molecular Immunology 2006 43 9 1349 1357 2-s2.0-33644824595 10.1016/j.molimm.2005.09.004 (Pubitemid 43356375)
210. + T cells in response to antagonist ligands. Journal of Experimental Medicine 1996 184 1 149 157 2-s2.0-0009542458 10.1084/jem.184.1.149 (Pubitemid 26247224)
211. Sykulev Y., Vugmeyster Y., Brunmark A., Ploegh H. L., Eisen H. N., Peptide antagonism and T cell receptor interactions with peptide-MHC complexes. Immunity 1998 9 4 475 483 2-s2.0-0032192366 10.1016/S1074-7613(00)80631-7 (Pubitemid 28499199)
212. Yachi P. P., Ampudia J., Zal T., Gascoigne N. R. J., Altered peptide ligands induce delayed CD8-T cell receptor interaction-a role for CD8 in distinguishing antigen quality. Immunity 2006 25 2 203 211 2-s2.0-33747092261 10.1016/j.immuni.2006.05.015 (Pubitemid 44224141)
213. Kessler B., Hudrisier D., Cerottini J. C., Luescher I. F., Role of CDd8 in aberrant function of cytotoxic T lymphocytes. Journal of Experimental Medicine 1997 186 12 2033 2038 2-s2.0-0031283021 10.1084/jem.186.12.2033 (Pubitemid 28013687)
214. Kessler B. M., Bassanini P., Cerottini J. C., Luescher I. F., Effects of epitope modification on T cell receptor-ligand binding and antigen recognition by seven H-2K(d)-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. Journal of Experimental Medicine 1997 185 4 629 640 2-s2.0-0031020465 10.1084/jem.185.4.629 (Pubitemid 27098148)
215. Ueno T., Tomiyama H., Fujiwara M., Oka S., Takiguchi M., Functionally impaired HIV-specific CD8 T cells show high affinity TCR-ligand interactions. Journal of Immunology 2004 173 9 5451 5457 2-s2.0-6344272217 (Pubitemid 39392129)
216. Rubio-Godoy V., Dutoit V., Rimoldi D., Lienard D., Lejeune F., Speiser D., Guillaume P., Cerottini J. C., Romero P., Valmori D., Discrepancy between ELISPOT IFN- γ secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proceedings of the National Academy of Sciences of the United States of America 2001 98 18 10302 10307 2-s2.0-17944367867 10.1073/pnas.181348898 (Pubitemid 32803015)
217. Andersen P. S., Geisler C., Buus S., Mariuzza R. A., Karjalainen K., Role of the T cell receptor ligand affinity in T cell activation by bacterial superantigens. Journal of Biological Chemistry 2001 276 36 33452 33457 2-s2.0-0035823601 10.1074/jbc.M103750200
218. Holler P. D., Kranz D. M., Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003 18 2 255 264 2-s2.0-0037331525 10.1016/S1074-7613(03)00019-0 (Pubitemid 36263000)
219. -T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. Journal of Experimental Medicine 2001 194 8 1043 1052 2-s2.0-0035887216 10.1084/jem.194.8.1043 (Pubitemid 32995776)
220. Slansky J. E., Rattis F. M., Boyd L. F., Fahmy T., Jaffee E. M., Schneck J. P., Margulies D. H., Pardoll D. M., Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000 13 4 529 538 2-s2.0-0033696977
221. Douat-Casassus C., Marchand-Geneste N., Diez E., Gervois N., Jotereau F., Quideau S., Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. Journal of Medicinal Chemistry 2007 50 7 1598 1609 2-s2.0-34147119079 10.1021/jm0613368 (Pubitemid 46564380)
222. Jeter J. M., Cranmer L. D., Hersh E. M., Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clinical Medicine Insights 2012 6 275 286
223. Peggs K. S., Quezada S. A., Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. Expert Review of Anticancer Therapy 2010 10 11 1697 1701 2-s2.0-78649242082 10.1586/era.10.144
224. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., van den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010 363 8 711 723 2-s2.0-77954801079 10.1056/NEJMoa1003466
225. + T-cell dependent. Blood 2006 108 12 3818 3823 2-s2.0-33751561177 10.1182/blood-2006-07-034066 (Pubitemid 44864564)
226. Gregor P. D., Wolchok J. D., Ferrone C. R., Buchinshky H., Guevara-Patiño J. A., Perales M. A., Mortazavi F., Bacich D., Heston W., Latouche J. B., Sadelain M., Allison J. P., Scher H. I., Houghton A. N., CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004 22 13-14 1700 1708 2-s2.0-11144353596 10.1016/j.vaccine. 2003.10.048 (Pubitemid 38447218)
227. Hernández J., Ko A., Sherman L. A., CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. Journal of Immunology 2001 166 6 3908 3914 2-s2.0-0035869571 (Pubitemid 32224917)
228. Hurwitz A. A., Yu T. F. Y., Leach D. R., Allison J. P., CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proceedings of the National Academy of Sciences of the United States of America 1998 95 17 10067 10071 2-s2.0-0032544067 10.1073/pnas.95.17.10067 (Pubitemid 28415295)
229. Paradis T. J., Floyd E., Burkwit J., Cole S. H., Brunson B., Elliott E., Gilman S., Gladue R. P., The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN γ Cancer Immunology, Immunotherapy 2001 50 3 125 133 2-s2.0-0034999020 10.1007/s002620100181 (Pubitemid 32480556)
230. Sabel M. S., Hess S. D., Egilmez N. K., Conway T. F. Jr., Chen F. A., Bankert R. B., CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. Cancer Immunology, Immunotherapy 2005 54 10 944 952 2-s2.0-23944490393 10.1007/s00262-005-0668-3 (Pubitemid 41187704)
231. + T cell- and IL-2-dependent mechanism. Immunity 1999 11 4 483 493 2-s2.0-0033213599 10.1016/S1074-7613(00)80123-5 (Pubitemid 29504203)
232. Sotomayor E. M., Borrello I., Tubb E., Allison J. P., Levitsky H. I., In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proceedings of the National Academy of Sciences of the United States of America 1999 96 20 11476 11481 2-s2.0-0033613173 10.1073/pnas.96.20.11476 (Pubitemid 29487405)
233. O'Day S. J., Hamid O., Urba W. J., Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007 110 12 2614 2627 2-s2.0-36849035139 10.1002/cncr.23086 (Pubitemid 350250330)
234. van der Merwe P. A., Bodian D. L., Daenke S., Linsley P., Davis S. J., CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. Journal of Experimental Medicine 1997 185 3 393 403 2-s2.0-0031054242 10.1084/jem.185.3.393 (Pubitemid 27078358)
235. Walunas T. L., Bakker C. Y., Bluestone J. A., CTLA-4 ligation blocks CD28-dependent T cell activation. Journal of Experimental Medicine 1996 183 6 2541 2550 2-s2.0-0029953858 10.1084/jem.183.6.2541 (Pubitemid 26192364)
236. + T-cell memory formation, function, and maintenance. Proceedings of the National Academy of Sciences of the United States of America 2011 108 1 266 271 2-s2.0-78651072784 10.1073/pnas.1016791108
237. Murphy M. L., Cotterell S. E. J., Gorak P. M. A., Engwerda C. R., Kaye P. M., Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. Journal of Immunology 1998 161 8 4153 4160 2-s2.0-0032532640 (Pubitemid 28468996)
238. + T cells by inhibiting ZAP-70 Tyr319 phosphorylation: a potential role for tyrosine phosphatases. Journal of Immunology 2002 168 9 4420 4429 2-s2.0-0036569236 (Pubitemid 34441343)
239. Marengère L. E. M., Waterhouse P., Duncan G. S., Mittrücker H. W., Feng G. S., Mak T. W., Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996 272 5265 1170 1173 2-s2.0-0030001318 (Pubitemid 26169471)
240. Schneider H., Smith X., Liu H., Bismuth G., Rudd C. E., CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization. European Journal of Immunology 2008 38 1 40 47 2-s2.0-38349074305 10.1002/eji.200737423
241. Garber K., Beyond ipilimumab: new approaches target the immunological synapse. Journal of the National Cancer Institute 2011 103 1079 1082 10.1093/jnci/djr281
242. Fife B. T., Pauken K. E., Eagar T. N., Obu T., Wu J., Tang Q., Azuma M., Krummel M. F., Bluestone J. A., Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nature immunology 2009 10 11 1185 1192 2-s2.0-70350433514 10.1038/ni.1790
243. Haspot F., Fehr T., Gibbons C., Zhao G., Hogan T., Honjo T., Freeman G. J., Sykes M., Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood 2008 112 5 2149 2155 2-s2.0-52649129667 10.1182/blood-2007-12-127449
244. + T cell tolerance to tissue antigens. Journal of Immunology 2006 177 12 8291 8295 2-s2.0-33845456174 (Pubitemid 44893788)
245. Wong R. M., Scotland R. R., Lau R. L., Wang C., Korman A. J., Kast W. M., Weber J. S., Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. International Immunology 2007 19 10 1223 1234 2-s2.0-34848900497 10.1093/intimm/dxm091 (Pubitemid 47500645)
246. Pilon-Thomas S., Mackay A., Vohra N., Mulé J. J., Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. Journal of Immunology 2010 184 7 3442 3449 2-s2.0-77951637543 10.4049/jimmunol.0904114
247. + T cell tolerance through PD-1 and CTLA-4. Nature Immunology 2005 6 3 280 286 2-s2.0-14944360112 10.1038/ni1165 (Pubitemid 41724765)
248. Curran M. A., Montalvo W., Yagita H., Allison J. P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America 2010 107 9 4275 4280 2-s2.0-77749279776 10.1073/pnas.0915174107
249. + T cells by B7-transfected melanoma cells. Science 1993 259 5093 368 370 2-s2.0-0027392843 (Pubitemid 23055679)
250. Harada M., Okamoto T., Omoto K., Tamada K., Takenoyama M., Hirashima C., Ito O., Kimura G., Nomoto K., Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies. Immunology 1996 87 3 447 453 2-s2.0-0029935669 (Pubitemid 26100187)
251. Suntharalingam G., Perry M. R., Ward S., Brett S. J., Castello-Cortes A., Brunner M. D., Panoskaltsis N., Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. The New England Journal of Medicine 2006 355 10 1018 1028 2-s2.0-33748416499 10.1056/NEJMoa063842 (Pubitemid 44343545)
252. Summers deLuca L., Gommerman J. L., Fine-tuning of dendritic cell biology by the TNF superfamily. Nature Reviews Immunology 2012 12 339 351
253. Dawicki W., Bertram E. M., Sharpe A. H., Watts T. H., 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. Journal of Immunology 2004 173 10 5944 5951 2-s2.0-8444234229 (Pubitemid 39487748)
254. Chen A. I., McAdam A. J., Buhlmann J. E., Scott S., Lupher M. L., Greenfield E. A., Baum P. R., Fanslow W. C., Calderhead D. M., Freeman G. J., Sharpe A. H., Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 1999 11 6 689 698 2-s2.0-0033427044 (Pubitemid 30030708)
255. Salek-Ardakani S., Flynn R., Arens R., Yagita H., Smith G. L., Borst J., Schoenberger S. P., Croft M., The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. Journal of Clinical Investigation 2011 121 1 296 307 2-s2.0-78650939319 10.1172/JCI42056
256. Salek-Ardakani S., Moutaftsi M., Sette A., Croft M., Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against
257. Dawicki W., Watts T. H., Expression and function of 4-IBB during CD4 versus CD8 T cell responses in vivo. European Journal of Immunology 2004 34 3 743 751 2-s2.0-1642314780 10.1002/eji.200324278 (Pubitemid 39255922)
258. Shao Z., Schwarz H., CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. Journal of Leukocyte Biology 2010 89 1 21 29 2-s2.0-78650769051 10.1189/jlb.0510315
259. de Keersmaecker B., Heirman C., Corthals J., Empsen C., van Grunsven L. A., Allard S. D., Pen J., Lacor P., Thielemans K., Aerts J. L., The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. Journal of Leukocyte Biology 2011 89 6 989 999 2-s2.0-79957868214 10.1189/jlb.0810466
260. Tone M., Tone Y., Adams E., Yates S. F., Frewin M. R., Cobbold S. P., Waldmann H., Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proceedings of the National Academy of Sciences of the United States of America 2003 100 25 15059 15064 2-s2.0-0345598872 10.1073/pnas.2334901100 (Pubitemid 37518016)
261. + T cells. Journal of Immunology 2004 173 8 5008 5020 2-s2.0-6344279933 (Pubitemid 39387783)
262. Snell L. M., McPherson A. J., Lin G. H. Y., Sakaguchi S., Pandolfi P. P., Riccardi C., Watts T. H., CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. Journal of Immunology 2010 185 12 7223 7234 2-s2.0-78650668092 10.4049/jimmunol.1001912
263. Kjaergaard J., Tanaka J., Kim J. A., Rothchild K., Weinberg A., Shu S., Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Research 2000 60 19 5514 5521 2-s2.0-0034306979
264. Miller R. E., Jones J., Le T., Whitmore J., Boiani N., Gliniak B., Lynch D. H., 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. Journal of Immunology 2002 169 4 1792 1800 2-s2.0-0037103147 (Pubitemid 34857639)
265. Taraban V. Y., Rowley T. F., O'Brien L., Chan H. T., Haswell L. E., Green M. H., Tutt A. L., Glennie M. J., Al-Shamkhani A., Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. European Journal of Immunology 2002 32 3617 3627 (Pubitemid 36024398)
266. Li B., Lin J., VanRoey M., Jure-Kunkel M., Jooss K., Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clinical Immunology 2007 125 1 76 87 2-s2.0-34548512807 10.1016/j.clim.2007.07.005 (Pubitemid 47374542)
267. Gough M. J., Ruby C. E., Redmond W. L., Dhungel B., Brown A., Weinberg A. D., OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Research 2008 68 13 5206 5215 2-s2.0-48549099849 10.1158/0008-5472.CAN-07-6484
268. Ruby C. E., Weinberg A. D., OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. Journal of Immunology 2009 182 3 1481 1489 2-s2.0-63149184826
269. Curran M. A., Kim M., Montalvo W., Al-Shamkhani A., Allison J. P., Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011 6 4 2-s2.0-79955785050 10.1371/journal.pone.0019499 e19499
270. Cohen A. D., Schaer D. A., Liu C., Li Y., Hirschhorn-Cymmerman D., Kim S. C., Diab A., Rizzuto G., Duan F., Perales M. A., Merghoub T., Houghton A. N., Wolchok J. D., Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010 5 5 2-s2.0-77955279163 10.1371/journal.pone.0010436 e10436
271. + regulatory T cells. Journal of Experimental Medicine 2005 202 7 885 891 2-s2.0-25844517914 10.1084/jem.20050940 (Pubitemid 41396888)
272. Piconese S., Valzasina B., Colombo M. P., OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. Journal of Experimental Medicine 2008 205 4 825 839 2-s2.0-42249097689 10.1084/jem.20071341 (Pubitemid 351549881)
273. + T cells. Cancer Research 2002 62 12 3459 3465 2-s2.0-0037096878 (Pubitemid 34651393)